Aldeyra Therapeutics (ALDX) News Today $2.19 +0.18 (+8.96%) Closing price 04:00 PM EasternExtended Trading$2.16 -0.02 (-1.14%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors are Reminded to Contact BFA Law about the Securities InvestigationApril 17 at 7:18 PM | markets.businessinsider.comALDX INVESTOR INVESTIGATION: Aldeyra Therapeutics, Inc. ...April 17 at 9:40 AM | gurufocus.comWhat is Leerink Partnrs' Estimate for ALDX Q2 Earnings?Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Aldeyra Therapeutics in a note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman expects that the biotechnology company willApril 17 at 7:46 AM | marketbeat.comQ2 Earnings Forecast for ALDX Issued By Leerink PartnrsApril 17 at 2:26 AM | americanbankingnews.comAldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap ...April 16 at 6:34 PM | gurufocus.comALDEYRA THERAPEUTICS, INC. (ALDX) Investors with Losses are Notified to Contact BFA Law about Pending Securities InvestigationApril 16 at 8:54 AM | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXApril 14 at 6:19 PM | prnewswire.comALDX STOCK UPDATE: Aldeyra Therapeutics, Inc. Investors are Reminded to Contact BFA Law about Pending Securities InvestigationApril 14 at 10:39 AM | markets.businessinsider.comKennedy Capital Management LLC Sells 412,559 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Kennedy Capital Management LLC decreased its position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 21.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,468,519 shares of tApril 14 at 5:59 AM | marketbeat.comALDX STOCK REMINDER: The Aldeyra Therapeutics, Inc. ...April 13, 2025 | gurufocus.comALDX STOCK REMINDER: The Aldeyra Therapeutics, Inc. Investigation is Ongoing – Investors are Urged to Contact BFA Law (NASDAQ:ALDX)April 13, 2025 | globenewswire.comALDX STOCK ALERT: BFA Law Alerts Aldeyra Therapeutics, Inc. Investors of the Ongoing Investigation into Securities ViolationsApril 11, 2025 | markets.businessinsider.comAldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens BermanApril 11, 2025 | globenewswire.comALDX STOCK NOTIFICATION: Did Aldeyra Therapeutics, Inc. Violate the Securities Laws? Investors are Notified to Contact BFA Law (NASDAQ:ALDX)April 11, 2025 | globenewswire.comALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Aldeyra Stockholders and Encourages Investors to Contact the FirmApril 10, 2025 | globenewswire.comALDX CLASS REMINDER: Aldeyra Therapeutics, Inc. Investors are Reminded to Contact BFA Law about the Pending Securities InvestigationApril 10, 2025 | markets.businessinsider.comAldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens BermanApril 10, 2025 | prnewswire.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Major Shareholder Perceptive Advisors Llc Sells 3,400,000 SharesAldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the firm's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total value of $4,828,000.00. Following the sale, the insider now directly owns 5,875,851 shares in the company, valued at approximately $8,343,708.42. This represents a 36.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.April 9, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities InvestigationApril 9, 2025 | markets.businessinsider.comAldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens BermanApril 9, 2025 | globenewswire.comAldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens BermanApril 9, 2025 | globenewswire.comBTIG Research Cuts Aldeyra Therapeutics (NASDAQ:ALDX) Price Target to $9.00BTIG Research reduced their price objective on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Monday.April 9, 2025 | marketbeat.comADAR1 Capital Management LLC Grows Stock Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)ADAR1 Capital Management LLC grew its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 114.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 647,960 shares of the biotechnology coApril 9, 2025 | marketbeat.comPerceptive Advisors Llc Sells 3,400,000 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) StockApril 9, 2025 | americanbankingnews.comBTIG Research Issues Pessimistic Forecast for Aldeyra Therapeutics (NASDAQ:ALDX) Stock PriceApril 9, 2025 | americanbankingnews.comALDX SECURITIES NOTIFICATION: Aldeyra Therapeutics, Inc. Investors that Suffered Losses are Notified to Contact BFA LawApril 8, 2025 | markets.businessinsider.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Major Shareholder Sells $4,828,000.00 in StockApril 8, 2025 | insidertrades.comALDX SECURITIES REPORT: Aldeyra Therapeutics, Inc. Securities Investigation Could Allow Investors to Recover Losses; Contact BFA Law (NASDAQ:ALDX)April 7, 2025 | globenewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Investors to Inquire about Securities InvestigationApril 6, 2025 | markets.businessinsider.comALDX SECURITIES NOTICE: Aldeyra Therapeutics, Inc. Investors with Losses are Notified to Contact BFA Law as they may have been Affected by Securities ViolationsApril 6, 2025 | markets.businessinsider.comAldeyra Therapeutics' (ALDX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a research report on Friday.April 6, 2025 | marketbeat.comALDX SECURITIES ALERT: Aldeyra Therapeutics, Inc. Investors are Notified of the Ongoing Securities Investigation; Contact BFA Law (NASDAQ:ALDX)April 5, 2025 | globenewswire.comALDX ALERT: BFA Law Informs Aldeyra Therapeutics, Inc. Investors to Contact the Firm about its Securities InvestigationApril 5, 2025 | markets.businessinsider.comKirby McInerney LLP Announces Investigation of Possible Claims Against Aldeyra Therapeutics, Inc. (ALDX) on Behalf of InvestorsApril 4, 2025 | globenewswire.comAldeyra options imply 35.3% move in share price post-earningsApril 4, 2025 | markets.businessinsider.comAldeyra down 75% after receiving CRL from FDA for reproxalapApril 3, 2025 | markets.businessinsider.comAldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease DrugApril 3, 2025 | marketwatch.comAldeyra Stock Slumps After FDA Says Investigational Drug For Dry Eyes Treatment Failed To Demonstrate Efficacy – Retail Stays OptimisticApril 3, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDXApril 3, 2025 | globenewswire.comAldeyra Therapeutics stock tumbles after FDA setbackApril 3, 2025 | in.investing.comALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. 75% Stock Drop; Investors are Notified to Contact BFA LawApril 3, 2025 | tmcnet.comAldeyra tumbles as FDA snubs dry eye disease therapyApril 3, 2025 | msn.comAldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays OptimisticApril 3, 2025 | msn.comAldeyra Therapeutics Stock Craters to All-Time Low on FDA LetterApril 3, 2025 | msn.comALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. 75% Stock Drop; Investors are Notified to Contact BFA LawApril 3, 2025 | businesswire.comALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock Drop Triggers Securities Investigation; Contact BFA Law if You Lost Money (NASDAQ:ALDX)April 3, 2025 | globenewswire.comBREAKING: Block & Leviton Investigating Aldeyra Therapeutics (ALDX) For Securities Fraud After Shares Fall Nearly 75%; Investors Encouraged to Contact the FirmApril 3, 2025 | globenewswire.comAldeyra Therapeutics tanks as FDA rejects investigational dry eye disease therapyApril 3, 2025 | proactiveinvestors.comFDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy ConcernsApril 3, 2025 | benzinga.comUS FDA declines to approve Aldeyra's eye disease drugApril 3, 2025 | reuters.com Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address ALDX Media Mentions By Week ALDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALDX News Sentiment▼0.350.64▲Average Medical News Sentiment ALDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALDX Articles This Week▼192▲ALDX Articles Average Week Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SVRA News Today QURE News Today BCYC News Today URGN News Today GHRS News Today KURA News Today CRMD News Today SAGE News Today MRVI News Today TYRA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALDX) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALDX Stock Free ALDX Stock Alerts